キタナカ　ジュンイチ   北中　純一    所属   兵庫医科大学  薬学部 医療薬学科    職種   准教授
言語種別	英語
発行・発表の年月	2022/08
形態種別	単行本
標題	Glycogen synthase kinase-3beta and methamphetamine abuse liability
執筆形態	共著
掲載誌名	Advances in Health and Disease (Lowell T. Duncan (Editor))
掲載区分	国外
出版社・発行元	Nova Science Publishers, Inc (New York)
巻・号・頁	Vol. 55,pp.161-180
担当範囲	Chapter 7
担当区分	筆頭著者,責任著者
国際共著	国際共著
著者・共著者	Junichi Kitanaka, Nobue Kitanaka, F. Scott Hall, Logan E. Kountz, Takuma Hashimoto, Kai Hirabayashi, Utau Horie, Kenta Iwasaki, Yumi Kawasaki, Minami Kimura, Takashi Sakamoto, Junya Yashiro, Kazuo Tomita, Kento Igarashi, Koh-ichi Tanaka, George R. Uhl, Tomoaki Sato, & Nobuyoshi Nishiyama
概要	Glycogen synthase kinase-3 (GSK-3) (EC2.7.11.26) is an essential serine/threonine kinase that has a role in a variety of physiological processes. GSK-3 is constitutively active, multifaceted, and ubiquitous in nature. In mammalian cells, GSK-has two isoforms termed GSK-3alpha and GSK-3beta. GSK-3beta is present in high concentrations in tissues in the central nervous system, having a crucial role in neuronal signaling pathways. Abnormal activity of GSK-3 is associated with neurodegenerative disorders including Alzheimer’s disease and Parkinson’s disease. In neurodegenerative disorders, GSK-3beta enzyme levels are elevated, so that the inhibition of GSK-3beta might be expected to diminish signaling dysfunctions in these conditions. Differences in GSK-3β function occur in many psychiatric and neurological conditions as well, including drug dependence, perhaps because this signaling pathway influences cell survival and synaptic plasticity.